# \[e-drug\] New report on AIDS and economics **URL:** \ **Category:** e-drug\ **Created:** [August 28, 2002, 2:56pm UTC](https://talk.edrugplus.org/t/e-drug-new-report-on-aids-and-economics/14850 "2002-08-28T14:56:47Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![e-drug2](https://avatars.discourse-cdn.com/v4/letter/e/8dc957/32.png) [@e-drug2](https://talk.edrugplus.org/u/e-drug2)\ **Post date:** [August 28, 2002, 2:56pm UTC](https://talk.edrugplus.org/t/e-drug-new-report-on-aids-and-economics/14850/1 "2002-08-28T14:56:47Z")
E-drug: New report on AIDS and economics ------------------------------------------------------------------------- [Copied from Ip-health. The full report is 129 pages. KM] Report from the POLICY Project, and Merck: State of the Art: AIDS and Economics [http://www.policyproject.com/pubs/other/SOTAecon.pdf](http://www.policyproject.com/pubs/other/SOTAecon.pdf) Section One: The Various Roles of Economics in Addressing the HIV/AIDS Pandemic (overview) Chapter 1: Current and Future Resources for HIV/AIDS William McGreevey, Stefano Bertozzi, Juan-Pablo Gutierrez, Marjorie Opuni, Jose-Antonio Izazola Chapter 2: HIV / AIDS and Globalization -- What Is the Epidemic Telling Us About Economics, Morality, and Pragmatism? Tony Barnett Chapter 3: The Economics of Social and Structural Interventions for HIV Prevention in Developing Countries Beena Varghese Section Two: Understanding the Impact of HIV/AIDS (overview) Chapter 4: HIV / AIDS, Health, and Education Alan Whiteside Chapter 5: How Does HIV / AIDS Affect African Business? Steven Forsythe Chapter 6: HIV / AIDS and Its Impact on Trade and Commerce Lori Bollinger Chapter 7: AIDS and Macroeconomic Impact Robert Greener Section Three: Using Economics to Respond to the Pandemic (overview) Chapter 8: Resource Allocation Within HIV / AIDS Programs John Stover, Lori Bollinger Chapter 9: Cost-Effectiveness and Economic Evaluation of HIV / AIDS-Related Interventions: The State of the Art Lilani Kumaranayake Chapter 10: Randomized Trials of HIV Prevention Interventions in Developing Countries Marjorie Opuni, Stefano Bertozzi, Lia Fernald, Juan-Pablo Gutierrez, Lisa DeMaria, Ken Morrison, Shanthi Noriega Chapter 11: Economics of HIV/AIDS Impact Mitigation: Re-sponding to Problems of Systemic Dysfunction and Sectoral Capacity Ishrat Husain Chapter 12: Antiretroviral Treatment for HIV-Infected Adults and Children in Developing Countries: Some Evidence In Favor of Ex-panded Diffusion J.P. Moatti, I. N�Doye, S.M. Hammer, P. Hale, M.D. Kazatchkine Conclusion �The success of the struggle against HIV/ AIDS will depend fundamentally on effective national leadership in the most affected countries. Recent signs of positive movement in that regard are encouraging. The recent and unprecedented actions of governments of Africa to increase their commitment to health care is one important step. The focus on HIV/AIDS within the Poverty Reduction Strategy Papers being prepared by 22 governments in the region to justify debt relief is another. International acceptance of the emergency nature of the crisis has led virtually all pharmaceutical companies to substantially reduce the barrier of high cost for antiretrovirals. Acting individually and collectively, the world�s high-income countries have also signalled that they recognize the need for an extraordinary boost to the fight against AIDS.� --Schwartlander, B et al. 2001. �Resource Needs for HIV/AIDS�. Science, 2434-2436. -- To send a message to E-Drug, write to: e-drug@usa.healthnet.org To subscribe or unsubscribe, write to: majordomo@usa.healthnet.org in the body of the message type: subscribe e-drug OR unsubscribe e-drug To contact a person, send a message to: e-drug-help@usa.healthnet.org Information and archives: [http://www.healthnet.org/programs/edrug.html](http://www.healthnet.org/programs/edrug.html)